Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00005062

NCT00005062
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with small cell lung cancer that is "limited stage," confirmed by a tissue sample (biopsy)
  • Your cancer has shown a complete response (disappeared, at least on chest X-ray) after your initial treatment
  • You have had a brain CT scan or MRI within the last month that came back normal
  • Your cancer has not spread to other parts of the body, including to the other lung or into fluid around the lungs
  • You are aged 70 or under
  • You are reasonably active and able to care for yourself (your doctor will assess this using a standard scale)

Who may not be able to join:

  • You have had a stroke or other blood vessel-related brain condition in the past
  • You have epilepsy that requires you to take medication by mouth on an ongoing basis
  • You have had another type of cancer before, unless it was a skin cancer or a very early-stage cervical cancer
  • You are currently receiving chemotherapy (other treatments may still be allowed — confirm with trial site)
  • You are currently taking any other anti-cancer treatment not specified as allowed (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Registry
clinicaltrials_gov
Start date
1 September 1999
Est. completion
1 December 2005

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇱 Chile 🇨🇳 China 🇨🇴 Colombia Cyprus 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇱🇹 Lithuania 🇳🇱 Netherlands North Macedonia 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇷🇸 Serbia 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇨🇭 Switzerland Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence of brain metastases 2 years after randomization

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov